Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 13/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCND2 | P30279 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356168 | 0.77 | STAT6 (0.57) | STAT6SYKCDK4CCND1CCND2 | |
| SCHEMBL1355309 | 0.75 | STAT6 (0.57) | STAT6SYKCDK4CCND1CCND2 | |
| SCHEMBL672453 | 0.74 | STAT6 (0.51) | STAT6SYKRPS6KA3CDK4CCND1 | |
| SCHEMBL671179 | 0.71 | STAT6 (0.54) | STAT6SYKRPS6KA3CDK4CCND1 | |
| SCHEMBL673237 | 0.71 | JAK2 (0.51) | STAT6SYKRPS6KA3CDK4CCND1 | |
| SCHEMBL10203830 | 0.71 | STAT6 (0.45) | STAT6SYKRPS6KA3CDK4CCND1 | |
| SCHEMBL1355968 | 0.69 | STAT6 (0.58) | STAT6CDK4CCND1CCND2CCND3 | |
| SCHEMBL1353743 | 0.69 | CDK4 (0.49) | STAT6CDK4CCND1CCND2CCND3 | |
| SCHEMBL21846878 | 0.69 | JAK3 (0.68) | STAT6 | |
| SCHEMBL29387386 | 0.69 | JAK3 (0.68) | STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
| CN-101616921-A | The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent | BIOGEN IDEC INC | 2009-12-30 | — | — | CN | disclosed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | STAT6 2214/4885SYK 1152/4885RPS6KA3 430/4885 |
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | STAT6 2276/4885SYK 1222/4885RPS6KA3 456/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | STAT6 2214/4885SYK 1152/4885RPS6KA3 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.